Does the media prefer GANX or DYAI?

In the previous week, Gain Therapeutics had 2 more articles in the media than Dyadic International. MarketBeat recorded 7 mentions for Gain Therapeutics and 5 mentions for Dyadic International. Gain Therapeutics' average media sentiment score of 0.53 beat Dyadic International's score of 0.00 indicating that Gain Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gain Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Dyadic International 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings and valuation, DYAI or OKYO?

Dyadic International has higher revenue and earnings than OKYO Pharma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Dyadic International $3.09M 5.91 -$7.36M -$0.23 N/A OKYO Pharma N/A N/A -$8.95M N/A N/A

Does the media refer more to DYAI or OKYO?

In the previous week, Dyadic International had 3 more articles in the media than OKYO Pharma. MarketBeat recorded 5 mentions for Dyadic International and 2 mentions for OKYO Pharma. Dyadic International's average media sentiment score of 0.00 equaled OKYO Pharma'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dyadic International 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral OKYO Pharma 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor DYAI or GOSS?

In the previous week, Dyadic International had 1 more articles in the media than Gossamer Bio. MarketBeat recorded 5 mentions for Dyadic International and 4 mentions for Gossamer Bio. Gossamer Bio's average media sentiment score of 0.63 beat Dyadic International's score of 0.00 indicating that Gossamer Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dyadic International 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Gossamer Bio 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate APLM or DYAI?

Dyadic International has a consensus price target of $3.00, suggesting a potential upside of 558.18%. Given Dyadic International's stronger consensus rating and higher possible upside, analysts plainly believe Dyadic International is more favorable than Apollomics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Apollomics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Dyadic International 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has preferable earnings and valuation, APLM or DYAI?

Dyadic International has lower revenue, but higher earnings than Apollomics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Apollomics $8.50M 8.10 -$10.94M N/A N/A Dyadic International $3.09M 5.91 -$7.36M -$0.23 N/A

Does the media refer more to KLRS or DYAI?

In the previous week, Dyadic International had 4 more articles in the media than Kalaris Therapeutics. MarketBeat recorded 5 mentions for Dyadic International and 1 mentions for Kalaris Therapeutics. Kalaris Therapeutics' average media sentiment score of 0.00 equaled Dyadic International'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kalaris Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Dyadic International 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Dyadic International (DYAI) Competitors

$0.46 0.00 (0.00%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$0.45 -0.01 (-1.71%)

As of 05:31 AM Eastern

Compare

DYAI vs. GANX, OKYO, GOSS, APLM, and KLRS

Should you buy Dyadic International stock or one of its competitors? Dyadic International's main competitors and comparable companies include Gain Therapeutics (GANX), OKYO Pharma (OKYO), Gossamer Bio (GOSS), Apollomics (APLM), and Kalaris Therapeutics (KLRS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Dyadic International compare to Gain Therapeutics?

Gain Therapeutics (NASDAQ:GANX) and Dyadic International (NASDAQ:DYAI) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, dividends, valuation, risk, media sentiment, profitability and institutional ownership.

In the previous week, Gain Therapeutics had 2 more articles in the media than Dyadic International. MarketBeat recorded 7 mentions for Gain Therapeutics and 5 mentions for Dyadic International. Gain Therapeutics' average media sentiment score of 0.53 beat Dyadic International's score of 0.00 indicating that Gain Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Gain Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Dyadic International	0 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Gain Therapeutics has a net margin of 0.00% compared to Dyadic International's net margin of -201.43%. Gain Therapeutics' return on equity of -161.59% beat Dyadic International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gain Therapeutics	N/A	-161.59%	-118.36%
Dyadic International	-201.43%	-2,920.31%	-84.77%

Dyadic International has higher revenue and earnings than Gain Therapeutics. Gain Therapeutics is trading at a lower price-to-earnings ratio than Dyadic International, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gain Therapeutics	$50K	1,492.49	-$20.16M	-$0.50	N/A
Dyadic International	$3.09M	5.91	-$7.36M	-$0.23	N/A

Gain Therapeutics has a beta of 0.19, meaning that its share price is 81% less volatile than the broader market. Comparatively, Dyadic International has a beta of 0.96, meaning that its share price is 4% less volatile than the broader market.

Gain Therapeutics presently has a consensus target price of $7.50, indicating a potential upside of 338.60%. Dyadic International has a consensus target price of $3.00, indicating a potential upside of 558.18%. Given Dyadic International's higher probable upside, analysts plainly believe Dyadic International is more favorable than Gain Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gain Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Dyadic International	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

12.0% of Gain Therapeutics shares are owned by institutional investors. Comparatively, 28.0% of Dyadic International shares are owned by institutional investors. 4.2% of Gain Therapeutics shares are owned by insiders. Comparatively, 20.9% of Dyadic International shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Dyadic International beats Gain Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Dyadic International compare to OKYO Pharma?

Dyadic International (NASDAQ:DYAI) and OKYO Pharma (NASDAQ:OKYO) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, earnings, media sentiment, risk, dividends and valuation.

In the previous week, Dyadic International had 3 more articles in the media than OKYO Pharma. MarketBeat recorded 5 mentions for Dyadic International and 2 mentions for OKYO Pharma. Dyadic International's average media sentiment score of 0.00 equaled OKYO Pharma'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dyadic International	0 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
OKYO Pharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

OKYO Pharma has a net margin of 0.00% compared to Dyadic International's net margin of -201.43%. OKYO Pharma's return on equity of 0.00% beat Dyadic International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dyadic International	-201.43%	-2,920.31%	-84.77%
OKYO Pharma	N/A	N/A	N/A

Dyadic International presently has a consensus price target of $3.00, suggesting a potential upside of 558.18%. OKYO Pharma has a consensus price target of $5.67, suggesting a potential upside of 285.49%. Given Dyadic International's higher possible upside, equities research analysts plainly believe Dyadic International is more favorable than OKYO Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dyadic International	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
OKYO Pharma	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Dyadic International has a beta of 0.96, indicating that its stock price is 4% less volatile than the broader market. Comparatively, OKYO Pharma has a beta of 0.05, indicating that its stock price is 95% less volatile than the broader market.

28.0% of Dyadic International shares are held by institutional investors. Comparatively, 3.0% of OKYO Pharma shares are held by institutional investors. 20.9% of Dyadic International shares are held by company insiders. Comparatively, 40.5% of OKYO Pharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Dyadic International has higher revenue and earnings than OKYO Pharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dyadic International	$3.09M	5.91	-$7.36M	-$0.23	N/A
OKYO Pharma	N/A	N/A	-$8.95M	N/A	N/A

Summary

Dyadic International and OKYO Pharma tied by winning 6 of the 12 factors compared between the two stocks.

How does Dyadic International compare to Gossamer Bio?

Dyadic International (NASDAQ:DYAI) and Gossamer Bio (NASDAQ:GOSS) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, analyst recommendations, valuation, risk, media sentiment and dividends.

Dyadic International has a net margin of -201.43% compared to Gossamer Bio's net margin of -235.00%. Gossamer Bio's return on equity of 0.00% beat Dyadic International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dyadic International	-201.43%	-2,920.31%	-84.77%
Gossamer Bio	-235.00%	N/A	-112.04%

28.0% of Dyadic International shares are held by institutional investors. Comparatively, 81.2% of Gossamer Bio shares are held by institutional investors. 20.9% of Dyadic International shares are held by insiders. Comparatively, 4.2% of Gossamer Bio shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Dyadic International has higher earnings, but lower revenue than Gossamer Bio. Dyadic International is trading at a lower price-to-earnings ratio than Gossamer Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dyadic International	$3.09M	5.91	-$7.36M	-$0.23	N/A
Gossamer Bio	$53.29M	1.23	-$170.37M	-$56.00	N/A

In the previous week, Dyadic International had 1 more articles in the media than Gossamer Bio. MarketBeat recorded 5 mentions for Dyadic International and 4 mentions for Gossamer Bio. Gossamer Bio's average media sentiment score of 0.63 beat Dyadic International's score of 0.00 indicating that Gossamer Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dyadic International	0 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Gossamer Bio	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Dyadic International currently has a consensus target price of $3.00, suggesting a potential upside of 558.18%. Gossamer Bio has a consensus target price of $256.00, suggesting a potential upside of 2,290.29%. Given Gossamer Bio's stronger consensus rating and higher possible upside, analysts clearly believe Gossamer Bio is more favorable than Dyadic International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dyadic International	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Gossamer Bio	2 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.22

Dyadic International has a beta of 0.96, meaning that its stock price is 4% less volatile than the broader market. Comparatively, Gossamer Bio has a beta of 2.21, meaning that its stock price is 121% more volatile than the broader market.

Summary

Gossamer Bio beats Dyadic International on 9 of the 16 factors compared between the two stocks.

How does Dyadic International compare to Apollomics?

Apollomics (NASDAQ:APLM) and Dyadic International (NASDAQ:DYAI) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, dividends, media sentiment, valuation and earnings.

Apollomics has a net margin of 0.00% compared to Dyadic International's net margin of -201.43%. Apollomics' return on equity of 0.00% beat Dyadic International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Apollomics	N/A	N/A	N/A
Dyadic International	-201.43%	-2,920.31%	-84.77%

Dyadic International has lower revenue, but higher earnings than Apollomics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Apollomics	$8.50M	8.10	-$10.94M	N/A	N/A
Dyadic International	$3.09M	5.91	-$7.36M	-$0.23	N/A

Apollomics has a beta of 1.54, meaning that its stock price is 54% more volatile than the broader market. Comparatively, Dyadic International has a beta of 0.96, meaning that its stock price is 4% less volatile than the broader market.

Dyadic International has a consensus price target of $3.00, suggesting a potential upside of 558.18%. Given Dyadic International's stronger consensus rating and higher possible upside, analysts plainly believe Dyadic International is more favorable than Apollomics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Apollomics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Dyadic International	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

19.1% of Apollomics shares are held by institutional investors. Comparatively, 28.0% of Dyadic International shares are held by institutional investors. 20.9% of Dyadic International shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Dyadic International had 5 more articles in the media than Apollomics. MarketBeat recorded 5 mentions for Dyadic International and 0 mentions for Apollomics. Apollomics' average media sentiment score of 0.00 equaled Dyadic International'saverage media sentiment score.

Company	Overall Sentiment
Apollomics	Neutral
Dyadic International	Neutral

Summary

Dyadic International beats Apollomics on 7 of the 13 factors compared between the two stocks.

How does Dyadic International compare to Kalaris Therapeutics?

Kalaris Therapeutics (NASDAQ:KLRS) and Dyadic International (NASDAQ:DYAI) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, risk, profitability, valuation and media sentiment.

Kalaris Therapeutics has a net margin of 0.00% compared to Dyadic International's net margin of -201.43%. Kalaris Therapeutics' return on equity of -71.71% beat Dyadic International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kalaris Therapeutics	N/A	-71.71%	-42.95%
Dyadic International	-201.43%	-2,920.31%	-84.77%

Kalaris Therapeutics has a beta of 0.42, indicating that its stock price is 58% less volatile than the broader market. Comparatively, Dyadic International has a beta of 0.96, indicating that its stock price is 4% less volatile than the broader market.

Dyadic International has higher revenue and earnings than Kalaris Therapeutics. Dyadic International is trading at a lower price-to-earnings ratio than Kalaris Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kalaris Therapeutics	N/A	N/A	-$43.44M	-$2.02	N/A
Dyadic International	$3.09M	5.91	-$7.36M	-$0.23	N/A

66.1% of Kalaris Therapeutics shares are owned by institutional investors. Comparatively, 28.0% of Dyadic International shares are owned by institutional investors. 68.1% of Kalaris Therapeutics shares are owned by company insiders. Comparatively, 20.9% of Dyadic International shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Kalaris Therapeutics presently has a consensus price target of $18.75, suggesting a potential upside of 594.44%. Dyadic International has a consensus price target of $3.00, suggesting a potential upside of 558.18%. Given Kalaris Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Kalaris Therapeutics is more favorable than Dyadic International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kalaris Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Dyadic International	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Dyadic International had 4 more articles in the media than Kalaris Therapeutics. MarketBeat recorded 5 mentions for Dyadic International and 1 mentions for Kalaris Therapeutics. Kalaris Therapeutics' average media sentiment score of 0.00 equaled Dyadic International'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kalaris Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Dyadic International	0 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Kalaris Therapeutics beats Dyadic International on 9 of the 14 factors compared between the two stocks.

Get Dyadic International News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DYAI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DYAI vs. The Competition

Export

Metric	Dyadic International	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$18.26M	$3.85B	$7.14B	$13.26B
Dividend Yield	N/A	3.65%	2.53%	17.33%
P/E Ratio	-1.98	13.06	275.01	26.04
Price / Sales	5.91	1,291.80	609.29	91.95
Price / Cash	N/A	39.04	27.22	34.69
Price / Book	15.19	17.24	11.20	6.34
Net Income	-$7.36M	-$23.20M	$3.50B	$381.61M
7 Day Performance	-1.98%	-2.85%	-1.98%	-0.73%
1 Month Performance	-12.38%	-10.81%	-6.31%	-4.68%
1 Year Performance	-60.71%	18.93%	7.99%	1.58%

Dyadic International Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DYAI Dyadic International	1.8986 of 5 stars	$0.46 flat	$3.00 +558.2%	-60.7%	$18.26M	$3.09M	N/A	5	News Coverage
GANX Gain Therapeutics	1.9879 of 5 stars	$1.68 -5.1%	$7.50 +346.4%	-10.9%	$73.32M	N/A	N/A	21	News Coverage Positive News High Trading Volume
OKYO OKYO Pharma	2.1911 of 5 stars	$1.36 -0.7%	$5.67 +316.7%	-28.3%	$71.90M	N/A	N/A	5	Gap Down
GOSS Gossamer Bio	2.9549 of 5 stars	$11.58 +0.5%	$256.00 +2,110.7%	-94.8%	$70.39M	$48.47M	N/A	162	Gap Up
APLM Apollomics	1.6227 of 5 stars	$24.18 +1.4%	N/A	N/A	$69.51M	$8.50M	N/A	15

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DYAI) was last updated on 10/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Dyadic International (DYAI) Competitors

DYAI vs. GANX, OKYO, GOSS, APLM, and KLRS

How does Dyadic International compare to Gain Therapeutics?

Summary

How does Dyadic International compare to OKYO Pharma?

Summary

How does Dyadic International compare to Gossamer Bio?

Summary

How does Dyadic International compare to Apollomics?

Summary

How does Dyadic International compare to Kalaris Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DYAI vs. The Competition

Dyadic International Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Dyadic International (DYAI) Competitors

DYAI vs. GANX, OKYO, GOSS, APLM, and KLRS

How does Dyadic International compare to Gain Therapeutics?

Does the media prefer GANX or DYAI?

Is GANX or DYAI more profitable?

Which has better earnings and valuation, GANX or DYAI?

Which has more volatility and risk, GANX or DYAI?

Do analysts recommend GANX or DYAI?

Do institutionals & insiders believe in GANX or DYAI?

Summary

How does Dyadic International compare to OKYO Pharma?

Does the media refer more to DYAI or OKYO?

Is DYAI or OKYO more profitable?

Do analysts rate DYAI or OKYO?

Which has more risk & volatility, DYAI or OKYO?

Do institutionals & insiders have more ownership in DYAI or OKYO?

Which has better earnings and valuation, DYAI or OKYO?

Summary

How does Dyadic International compare to Gossamer Bio?

Is DYAI or GOSS more profitable?

Do insiders and institutionals hold more shares of DYAI or GOSS?

Which has better earnings & valuation, DYAI or GOSS?

Does the media favor DYAI or GOSS?

Do analysts recommend DYAI or GOSS?

Which has more volatility and risk, DYAI or GOSS?

Summary

How does Dyadic International compare to Apollomics?

Is APLM or DYAI more profitable?

Which has preferable earnings and valuation, APLM or DYAI?

Which has more volatility and risk, APLM or DYAI?

Do analysts rate APLM or DYAI?

Do institutionals and insiders have more ownership in APLM or DYAI?

Does the media prefer APLM or DYAI?

Summary

How does Dyadic International compare to Kalaris Therapeutics?

Is KLRS or DYAI more profitable?

Which has more risk and volatility, KLRS or DYAI?

Which has stronger valuation and earnings, KLRS or DYAI?

Do institutionals and insiders have more ownership in KLRS or DYAI?

Do analysts recommend KLRS or DYAI?

Does the media refer more to KLRS or DYAI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DYAI vs. The Competition

Dyadic International Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools